FDA Approves New Covid-19 Vaccine for High-Risk Groups

The US Food and Drug Administration (FDA) has granted approval for a new Covid-19 vaccine, although access is currently limited to high-risk populations.

On Wednesday, HHS Secretary Robert F. Kennedy shared news of the FDA’s decision in a post on X, stating, “I promised four things: 1. To end the Covid vaccine mandate, 2. To call for a placebo-controlled trial for companies providing vaccines to especially vulnerable individuals, and 4. To conclude the emergency declarations.” He felt that the agency met all four of these objectives.

Measles Outbreak Declared Over

RFK indicated that the FDA has granted “marketing authorization” to the upcoming vaccine options from Pfizer (for those ages 5 and older) and Novavax (for ages 12 and older). He mentioned that these vaccines would be available to patients after consulting with their doctors.

High-risk groups identified include individuals over 65 and those more likely to face severe complications from Covid, including many chronic conditions like asthma, cancer, heart disease, and diabetes, among others.

Pushback from Medical Groups

In a note on the CDC website, various conditions that heighten the risk of severe illness are outlined. RFK also pointed out that the previous emergency use authorizations for the Covid vaccine have now been revoked.

“The American public wanted scientific guidance, safety, and practical solutions,” RFK emphasized. “This new framework delivers on those demands.”

Before this shift, the Centers for Disease Control and Prevention had recommended vaccines to all Americans who had been in the country for more than six months.

Revision of Vaccination Guidelines

In May 2025, HHS Director Robert F. Kennedy Jr. declared that the Covid-19 vaccine would be removed from the standard vaccination schedule for healthy children.

This new guidance encourages “shared clinical decisions,” meaning that parents and healthcare providers should discuss the individual benefits and risks of vaccination for children rather than following a universal recommendation.

Despite these changes, the American Academy of Pediatrics (AAP) remains part of the annual vaccination guidelines.

Dr. Marc Siegel, a senior medical analyst, previously stated, “It should be a discussion among pediatricians, patients, and parents, as it largely depends on the child’s health and the current Covid situation.”